@afpcoaching's IGF-1 and peptide claims, fact-checked
Quick answer
Ipamorelin and CJC-1295 are growth hormone-releasing peptides that can increase IGF-1 levels but aren't FDA-approved for anti-aging or body composition enhancement. Normal IGF-1 ranges are age-adjusted, and routine testing isn't recommended for healthy adults without specific growth hormone deficiency symptoms.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What does this video actually claim?
Ivan Birkas claims most men over 40 have low IGF-1 levels (around 120 when they should be 250), causing stubborn fat, poor recovery, low testosterone, and bad lipid profiles. He suggests testing IGF-1 as a proxy for growth hormone and offers to guide followers through using ipamorelin and CJC-1295 peptides.
The post positions IGF-1 testing as a single diagnostic solution for multiple metabolic issues. It promises a straightforward protocol using growth hormone-releasing peptides to address these problems based on lab results.
Are the IGF-1 claims accurate?
The numbers Birkas cites don't match established reference ranges. Most labs use age-adjusted IGF-1 ranges, with men 40-50 typically ranging from 101-267 ng/mL, not a universal target of 250.
The NHANES III study (Brabant et al., Clinical Endocrinology, 2003) found IGF-1 naturally declines with age, dropping about 14% per decade after age 30. A 45-year-old man with IGF-1 of 120 ng/mL might be completely normal, not deficient.
While IGF-1 does correlate with growth hormone output, it's influenced by nutrition, liver function, and other factors. The American Association of Clinical Endocrinologists doesn't recommend routine IGF-1 testing in healthy adults without specific symptoms of growth hormone disorders.
Do these peptides actually work?
Both ipamorelin and CJC-1295 can increase growth hormone release, but the clinical evidence for body composition benefits is limited. A 2015 study (Sigalos et al., Maturitas) found CJC-1295 increased GH and IGF-1 levels but didn't measure body fat or muscle mass changes.
The most strong data comes from actual growth hormone therapy, not peptides. The GH-2000 study (Johannsson et al., Journal of Clinical Endocrinology, 2009) found growth hormone replacement in deficient adults improved body composition but required careful monitoring for side effects like joint pain and insulin resistance.
Birkas oversells the connection between low IGF-1 and testosterone. While growth hormone and testosterone pathways interact, treating one doesn't automatically fix the other.
What are the actual risks here?
The FDA hasn't approved ipamorelin or CJC-1295 for anti-aging or body composition purposes. Most peptide clinics operate in a regulatory gray area, selling these compounds as research chemicals.
Growth hormone stimulation can worsen insulin resistance and increase diabetes risk. A 2019 meta-analysis (Liu et al., Cochrane Database) found growth hormone therapy in non-deficient adults caused more side effects than benefits.
Birkas offers to guide peptide protocols through DMs, which bypasses proper medical oversight. These compounds need monitoring for glucose levels, joint symptoms, and potential tumor growth if someone has undiagnosed cancer.
What should you actually know?
IGF-1 testing makes sense if you have specific symptoms of growth hormone deficiency: severe fatigue, muscle weakness, or documented pituitary problems. It's not a routine screening test for feeling tired at 45.
The symptoms Birkas attributes to low IGF-1 (stubborn fat, poor recovery, low testosterone) have many causes. Sleep disorders, insulin resistance, and hypogonadism all need specific evaluation and treatment.
If you're genuinely concerned about growth hormone deficiency, see an endocrinologist. They'll do proper stimulation testing beyond just IGF-1 levels and can prescribe FDA-approved growth hormone if you actually need it.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @afpcoaching's IGF-1 and peptide claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Ipamorelin, the first selective growth hormone secretagogue
Background source for ipamorelin selectivity and GH-secretagogue mechanism.
PubMed
The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation
Preclinical context that should not be overstated as consumer clinical evidence.
PubMed
GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis
Used for PCOS pages comparing metabolic and weight-management approaches.
PubMed
The efficacy and safety of GLP-1 agonists in PCOS women living with obesity
Supports PCOS, obesity, and hormonal-regulation context.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
@afpcoaching's IGF-1 and peptide claims, fact-checked should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Claim path
Keep researching this ipamorelin video claims cluster
Best for searchers comparing ipamorelin claims with CJC-1295, sermorelin, and growth-hormone peptide evidence.
Claim verdict
The useful answer behind this video
Claim being checked
Ipamorelin and CJC-1295 are growth hormone-releasing peptides that can increase IGF-1 levels but aren't FDA-approved for anti-aging or body composition enhancement.
FormBlends verdict
Ipamorelin and CJC-1295 are growth hormone-releasing peptides that can increase IGF-1 levels but aren't FDA-approved for anti-aging or body composition enhancement. Normal IGF-1 ranges are age-adjusted, and routine testing isn't recommended for healthy adults without specific growth hormone deficiency symptoms.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Ipamorelin and CJC-1295 are growth hormone-releasing peptides that can increase IGF-1 levels but aren't FDA-approved for anti-aging or body composition enhancement. Normal IGF-1 ranges are age-adjusted, and routine testing isn't recommended for healthy adults without specific growth hormone deficiency symptoms.
- Normal IGF-1 ranges are age-adjusted, with men 40-50 typically ranging 101-267 ng/mL, not a universal target of 250
- IGF-1 naturally declines about 14% per decade after age 30 according to NHANES III data
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Normal IGF-1 ranges are age-adjusted, with men 40-50 typically ranging 101-267 ng/mL, not a universal target of 250
- IGF-1 naturally declines about 14% per decade after age 30 according to NHANES III data
- The FDA hasn't approved ipamorelin or CJC-1295 for anti-aging or body composition purposes
- Growth hormone stimulation can worsen insulin resistance and increase diabetes risk in non-deficient adults
- Symptoms like stubborn fat and poor recovery have multiple causes beyond growth hormone deficiency
- Proper growth hormone deficiency diagnosis requires stimulation testing by an endocrinologist, not just IGF-1 levels
- Most peptide clinics operate in regulatory gray areas, selling compounds as research chemicals rather than approved medications
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
IVAN BIRKAS | Metabolic Performance · Instagram creator
21.4K views on this video
Most men who come to me have never had their IGF-1 tested. That’s the proxy for your growth hormone output. And in men over 40 it’s almost always low — usually sitting around 120 when it should be cl
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by IVAN BIRKAS | Metabolic Performance, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.